drugset / Trial / NCT00885534
Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma
NaSingle-groupOpen-labelTreatment
Summary
The investigators want to learn to predict which tumors will respond to CVT chemotherapy. CVT is a combination of three drugs - cisplatin, vinblastine, and temozolomide. We and other investigators have used CVT in melanoma patients and found that tumors got significantly smaller in 30-40% of cases. In this study, the investigators want to get a precise idea of how many patients will respond to CVT. Also they want to test which genes in the tumor are turned on and which are turned off. We hope this will teach us to know in the future which tumors will respond to CVT.
Timeline
- Start
- 2009-04
- Primary completion
- 2013-10
- Completion
- 2013-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 25 mg/m2 | Intravenous |
| Subject | Dacarbazine | Small molecule | 800 mg/m2 | Intravenous |
| Subject | Temozolomide | Small molecule | 150 mg/m2 | Oral |
| Subject | Vinblastine | Small molecule | 1.5 mg/m2 | Intravenous |